肠道微生物组与抗CD19 CAR T细胞治疗反应及毒性的相关性
该多中心研究探讨肠道微生物组对B细胞淋巴瘤和白血病患者抗CD19 CAR T细胞治疗结局的影响。回顾性队列(n=228)发现治疗前4周抗生素暴露(尤其哌拉西林/他唑巴坦、美罗培南、亚胺培南/西司他丁)与更差生存和神经毒性增加相关;前瞻性队列(n=48)粪便微生物组在基线即与健康对照不同,特定细菌分类群和代谢通路与临床结局相关,梭菌纲某些物种与第100天完全缓解相关。
要点
- 治疗前4周抗生素暴露与更差生存和神经毒性增加相关。
- CAR T细胞受者基线粪便微生物组与健康对照不同。
- 梭菌纲某些物种与第100天完全缓解相关。
核心结论
- 肠道微生物组的变化与B细胞恶性肿瘤患者接受抗CD19 CAR T细胞治疗后的临床结局相关。
研究设计与样本
- 多中心研究,包括回顾性队列(n=228)和前瞻性CAR T细胞受者队列(n=48),粪便样本采用16S核糖体RNA和宏基因组鸟枪法测序分析。
主要发现
- 回顾性队列(n=228)中,治疗前4周暴露于抗生素,特别是哌拉西林/他唑巴坦、美罗培南和亚胺培南/西司他丁(P-I-M),与更差生存和神经毒性增加相关。
- 前瞻性队列(n=48)中,CAR T细胞受者基线粪便微生物组与健康对照相比发生改变。
- 16S核糖体RNA和宏基因组鸟枪法测序分析显示,临床结局与特定细菌分类群和代谢通路的差异相关。
- 通过非靶向和假设驱动分析,鉴定出梭菌纲内某些物种与第100天完全缓解相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has led to unprecedented responses in patients with high-risk hematologic malignancies. However, up to 60% of patients still experience disease relapse and up to 80% of patients experience CAR-mediated toxicities, such as cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. We investigated the role of the intestinal microbiome on these outcomes in a multicenter study of patients with B cell lymphoma and leukemia. We found in a retrospective cohort (n = 228) that exposure to antibiotics, in particular piperacillin/tazobactam, meropenem and imipenem/cilastatin (P-I-M), in the 4 weeks before therapy was associated with worse survival and increased neurotoxicity. In stool samples from a prospective cohort of CAR T cell recipients (n = 48), the fecal microbiome was altered at baseline compared to healthy controls. Stool sample profiling by 16S ribosomal RNA and metagenomic shotgun sequencing revealed that clinical outcomes were associated with differences in specific bacterial taxa and metabolic pathways. Through both untargeted and hypothesis-driven analysis of 16S sequencing data, we identified species within the class Clostridia that were associated with day 100 complete response. We concluded that changes in the intestinal microbiome are associated with clinical outcomes after anti-CD19 CAR T cell therapy in patients with B cell malignancies.
引用
- Smith M, Dai A, Ghilardi G, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022. PMID: 35288695. doi:10.1038/s41591-022-01702-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。